Paperless validation at its North American sites will expedite drug discovery methods and delivery to patients.
SAN FRANCISCO, Nov. 6, 2018 /PRNewswire/
ValGenesis, Inc., a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), today announced that the second largest pharmaceutical company in Japan has chosen to implement ValGenesis’ s 100% paperless Validation Lifecycle Management System to manage its corporate validation lifecycle process.
With corporate origins in Japan, this global pharmaceutical company provides innovative products and services in more than twenty countries around the world. It has more than 100 years of scientific expertise, draws upon a rich legacy of innovation and possesses a robust pipeline of promising new medicines that could enhance the lives of millions of people around the world. With 15,000 employees worldwide, they are creating both new and generic medicines, as well as new methods of drug discovery and delivery. The company is working towards its 2025 vision of becoming a global pharma innovator with competitive advantage in oncology.
Recognizing that traditional, manual, paper-based validation processes are costly and inefficient, the company has selected ValGenesis Enterprise VLMS—an electronic, paperless, cloud-based SaaS solution that well meets its lifecycle validation needs. With ValGenesis Enterprise VLMS, the company will significantly reduce validation cycle time, gain a higher standard of data integrity, improve its regulatory compliance process, and gain a holistic view of real-time validation status across its regulated systems, thereby improving the quality and speed of the entire process.
“I am happy with our continued success, especially with companies such as this global pharmaceutical who continue to select ValGenesis to meet their validation needs,” says Narayan Raj, Vice President of ValGenesis Inc. “Being a market leader in electronic Validation Lifecycle Management Solutions, it is our responsibility to provide a quality solution to our customers as they strive to discover innovative methods and medicines.”
Althea D’Sylva, ValGenesis Communications, +1 401 262 5911 Ex. 1026,
ValGenesis, Inc. is the inventor of an innovative software platform that serves as the foundation for managing compliance-based validation activities in Life Science companies. ValGenesis, Inc. provides the first enterprise application that manages the corporate validation lifecycle process. As the only system for managing validation execution and approval 100% electronically, ValGenesis was selected by an industry peer review committee to receive the Parenteral Drug Association (PDA) New Innovative Technology Award. ValGenesis solutions are fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements.
For more information, visit https://www.valgenesis.com